Liebmann M, Hucke S, Koch K, Eschborn M, Ghelman J, Chasan AI, Glander S, Schädlich M, Kuhlencord M, Daber NM, Eveslage M, Beyer M, Dietrich M, Albrecht P, Stoll M, Busch KB, Wiendl H, Roth J, Kuhlmann T, and Klotz L
T cells critically depend on reprogramming of metabolic signatures to meet the bioenergetic demands during activation and clonal expansion. Here we identify the transcription factor Nur77 as a cell-intrinsic modulator of T cell activation. Nur77-deficient T cells are highly proliferative, and lack of Nur77 is associated with enhanced T cell activation and increased susceptibility for T cell-mediated inflammatory diseases, such as CNS autoimmunity, allergic contact dermatitis and collagen-induced arthritis. Importantly, Nur77 serves as key regulator of energy metabolism in T cells, restricting mitochondrial respiration and glycolysis and controlling switching between different energy pathways. Transcriptional network analysis revealed that Nur77 modulates the expression of metabolic genes, most likely in close interaction with other transcription factors, especially estrogen-related receptor α. In summary, we identify Nur77 as a transcriptional regulator of T cell metabolism, which elevates the threshold for T cell activation and confers protection in different T cell-mediated inflammatory diseases., Competing Interests: Conflict of interest statement: S.H. has received speaker honoraria from Novartis. M.E. has received speaker honoraria and travel support from Sanofi Genzyme. M.D. had received speaker honoraria from Novartis. P.A. has received compensation for serving on Scientific Advisory Boards for Ipsen, Novartis, and Biogen; speaker honoraria and travel support from Novartis, Teva, Biogen, Merz Pharmaceuticals, Ipsen, Allergan, Bayer Healthcare, Esai, UCB, and Glaxo Smith Kline; and research support from Novartis, Biogen, Teva, Merz Pharmaceuticals, Ipsen, and Roche. H.W. has received compensation for serving on Scientific Advisory Boards/Steering Committees for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma, and Sanofi-Genzyme; speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma, Sanofi-Genzyme, TEVA, and WebMD Global; compensation as a consultant from Abbvie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society; and research support from German Ministry for Education and Research, German Research Foundation, Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, North Rhine-Westphalia Ministry of Education and Research, Interdisciplinary Center for Clinical Studies Muenster, Rasmussen Encephalitis Children’s Foundation, Biogen, GlaxoSmithKline, Roche Pharma, and Sanofi-Genzyme. L.K. has received compensation for serving on Scientific Advisory Boards for Genzyme and Novartis; speaker honoraria and travel support from Novartis, Merck Serono, Roche, Genzyme, and Biogen; and research support from Novartis and Biogen. T.K. has received honoraria for lecturing from Novartis, Merck Serono, Sanofi Aventis Bayer Health Care, and TEVA.